Quest Diagnostics Incorporated (DGX): Price and Financial Metrics


Quest Diagnostics Incorporated (DGX)

Today's Latest Price: $120.83 USD

0.63 (0.52%)

Updated Oct 19 6:30pm

Add DGX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

DGX Stock Summary

  • DGX has a higher market value than 88.8% of US stocks; more precisely, its current market capitalization is $16,143,176,246.
  • With a one year PEG ratio of 564.28, Quest Diagnostics Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 93.75% of US stocks.
  • Of note is the ratio of Quest Diagnostics Inc's sales and general administrative expense to its total operating expenses; 98.31% of US stocks have a lower such ratio.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Quest Diagnostics Inc are HUBB, MKC, WRK, MIDD, and IEX.
  • DGX's SEC filings can be seen here. And to visit Quest Diagnostics Inc's official web site, go to www.questdiagnostics.com.

DGX Stock Price Chart Interactive Chart >

Price chart for DGX

DGX Price/Volume Stats

Current price $120.83 52-week high $131.81
Prev. close $120.20 52-week low $73.02
Day low $120.31 Volume 1,075,843
Day high $121.77 Avg. volume 1,543,107
50-day MA $115.00 Dividend yield 1.86%
200-day MA $109.85 Market Cap 16.23B

Quest Diagnostics Incorporated (DGX) Company Bio


Quest Diagnostics provides diagnostic testing information services in the United States and internationally. The company offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, as well as related services and insights; laboratory testing services for new drugs, vaccines, and medical devices, analytic, on-site prevention, and wellness services, and risk assessment services for the life insurance industry. The company was founded in 1967 and is founded in Madison, New Jersey.

DGX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$120.83$86.61 -28%

Below please find a table outlining a discounted cash flow forecast for DGX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Quest Diagnostics Inc ranked in the 39th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for DGX, they are:

  • As a business, DGX is generating more cash flow than 76.33% of positive cash flow stocks in the Healthcare.
  • Quest Diagnostics Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than only 14.75% of tickers in our DCF set.
  • DGX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than only 14.75% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-29%
1%-29%
2%-28%
3%-27%
4%-27%
5%-26%

STE, PAHC, BDX, CNC, and EBS can be thought of as valuation peers to DGX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


DGX Latest News Stream


Event/Time News Detail
Loading, please wait...

DGX Latest Social Stream


Loading social stream, please wait...

View Full DGX Social Stream

Latest DGX News From Around the Web

Below are the latest news stories about Quest Diagnostics Inc that investors may wish to consider to help them evaluate DGX as an investment opportunity.

Quest's stock gains after announcing diagnostics that test for both COVID-19 and the flu

Shares of Quest Diagnostics Inc. undefined gained 3.1% in premarket trading on Wednesday after the company said it is now offering three panel tests that can…

MarketWatch | September 30, 2020

Quest Diagnostics Launches Three New Combined COVID-19 and Respiratory Virus Tests

SECAUCUS, N.J., Sept. 30, 2020 /PRNewswire/ -- Healthcare providers across the United States can now access three different test options from Quest Diagnostics (NYSE: DGX) to aid the diagnosis of COVID-19 and differentiate it from other seasonal respiratory infections, including influenza…

PR Newswire | September 30, 2020

Quest Diagnostics launches three new combined COVID-19, respiratory tests ahead of flu season

Quest Diagnostics has launched a 3-in-1 COVID-19 test that will work from a single swab. Yahoo Finance’s Alexis Christoforous, Brian Sozzi, and Anjalee Khemlani discuss the test, and the latest details in the race for a vaccine.

Yahoo Finance | September 30, 2020

Walmart teamed up with Quest Diagnostics to pilot drone delivery for coronavirus test kits

Summary List Placement Retail behemoth Walmart is teaming up with clinical lab giant Quest Diagnostics to test delivering coronavirus nasal swab kits via drones to eligible homes in Las Vegas and Cheektowaga, New York. To participate, customers must reside within a 1-mile radius of a Walmart store in these regions and mail in the completed nasal swab to Quest Diagnostics for their test results. Walmart's latest move highlights how retail pharmacies have leveraged drone delivery during the pandemic—but we think it will have limited utility in the broader healthcare space. For instance, CVS made similar moves earlier this year when it partnered with UPS to offer Florida retirement facilities drone delivery for prescription drugs. However, drone manufacturers must overcome a number of regu...

Business Insider | September 24, 2020

Global Helicobacter Pylori Diagnostics Market (2020 to 2024) - Featuring Abbott Laboratories, bioMerieux & Quest Diagnostics Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Helicobacter Pylori Diagnostics Market 2020-2024" report has been added to ResearchAndMarkets.com's offering. The helicobacter pylori diagnostics market is poised to grow by $ 209.59 million during 2020-2024 progressing at a CAGR of 8% during the forecast period. The reports on helicobacter pylori diagnostics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 ve

Business Wire | September 18, 2020

Read More 'DGX' Stories Here

DGX Price Returns

1-mo 6.64%
3-mo -5.58%
6-mo 22.52%
1-year 20.35%
3-year 35.41%
5-year 105.86%
YTD 15.70%
2019 31.13%
2018 -13.84%
2017 9.16%
2016 31.90%
2015 8.37%

DGX Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full DGX Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8794 seconds.